Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity-Reference-Cited by-同舟云学术

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Published:2010-12 Issue:12 Volume:11 Page:1149-1159
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wilson Wyndham H,O'Connor Owen A,Czuczman Myron S,LaCasce Ann S,Gerecitano John F,Leonard John P,Tulpule Anil,Dunleavy Kieron,Xiong Hao,Chiu Yi-Lin,Cui Yue,Busman Todd,Elmore Steven W,Rosenberg Saul H,Krivoshik Andrew P,Enschede Sari H,Humerickhouse Rod A

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes;Merino;EMBO J,1994

2. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation;Tsujimoto;Science,1984

3. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining;Tsujimoto;Science,1985

4. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma;Davis;Nature,2010

5. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death;Hockenbery;Nature,1990

Cited by 708 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated analysis of ferroptosis and stemness based on single-cell and bulk RNA-sequencing data provide insights into the prognosis and treatment of esophageal carcinoma;Gene;2024-11

2. Cellular senescence: A novel therapeutic target for central nervous system diseases;Biomedicine & Pharmacotherapy;2024-10

3. The Aging Immune System: A Critical Attack on Ischemic Stroke;Molecular Neurobiology;2024-09-14

4. Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia;Biomacromolecules;2024-09-05

5. Protein isoform-centric therapeutics: expanding targets and increasing specificity;Nature Reviews Drug Discovery;2024-09-04